Built on science.

Driven by patients.

A team with deep roots in formulation science and a shared belief that better delivery means better lives.

“

What our technology does is take a high dose of a biologic and condense it down into a volume small enough to be given as a subcutaneous injection. That means a simple syringe or pen device that patients can self-administer at home.

Deborah Bitterfield, PhD, CEO & Founder, Lindy BiosciencesInvestment Reports / The New Era of Life Sciences (April 2026)

Patients shouldn't have to reorganize their lives around their treatment schedule.

When Lindy Biosciences was founded in 2016, we saw an opportunity to address a longstanding challenge in biologic drug delivery. While many biologics offer significant therapeutic benefit, formulation limitations have historically confined high-dose therapies to IV administration — often requiring patients to spend hours receiving treatment in a clinical setting.

Built on technology originating from research at Duke University, Lindy Biosciences was founded to solve that problem. By developing highly concentrated biologic suspensions for subcutaneous administration, we are helping expand what's possible for biologic drug delivery.

Today, Lindy's suspension platform is the subject of a global licensing agreement and is attracting growing interest from pharmaceutical companies seeking new delivery options for high-dose biologics. Our rapid progress is a testament to what happens when deep formulation science meets a commitment to changing the rhythm of patient care.

Our Mission

To advance formulation science in ways that expand what's possible for biologic drug delivery. By enabling highly concentrated biologic suspensions for subcutaneous administration, we're helping reduce treatment burden for patients while creating new opportunities for pharmaceutical innovation.